AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Investor	Date	% Owned	Market Value	Shares	Chg. Shares	Chg. Shares %	% Portfolio
Government Pension Fund Global	2024-06-30	1.24651%	$3.75B	22.02M	1.58M	7.73%	0.35%
UBS Asset Management AG	2024-06-30	1.21553%	$3.66B	21.47M	2.21M	11.46%	0.46%
T. Rowe Price Group, Inc.	2024-06-30	0.89274%	$2.69B	15.77M	187.85K	1.21%	0.28%
JPMorgan Chase & Co, Private Banking and Investment Banking Investments	2024-06-30	0.42279%	$1.27B	7.47M	491.22K	7.04%	0.4%
Deutsche Asset & Wealth Management	2024-06-30	0.41251%	$1.24B	7.29M	-501.27K	-6.44%	0.43%
HSBC Global Asset Management (UK) Limited
AllianceBernstein L.P.
Nikko Asset Management Co., Ltd.
TD Asset Management, Inc.
Invesco Capital Management LLC
Invesco Ltd.
Strategic Advisers LLC
Stifel Asset Management Corp.
Mitsubishi UFJ Asset Management Co., Ltd.
Mackenzie Financial Corporation
Swedbank Robur Fonder AB
abrdn plc
Schroder Investment Management Limited
Neuberger Berman Investment Advisers LLC
Credit Suisse Asset Management (Switzerland) Ltd.

AbbVie Inc.

Top Holders